Abbott Gears Up For New Cholesterol Therapies, Winds Down Diagnostics
Executive Summary
Building on two strategic initiatives announced last year - the acquisition of Kos and a collaboration with AstraZeneca - Abbott is gearing up to expand its commercial presence and late-stage pipeline in the cholesterol treatment market this year, President and Chief Operating Officer Richard Gonzalez said during the company's year-end sales and earnings call Jan. 24
You may also be interested in...
Abbott Cardiovascular Franchise Swells; Combo Waves Will Crest in 2009
Abbott plans to submit a fixed-dose statin-fenofibrate combination with AstraZeneca's Crestor in 2009, the company reported during a June 18 sales and earnings call
Schering Tries To Lower Merck HDL Agent Expectations, Without Razing JV
Schering-Plough is downplaying the potential impact of Merck's investigational niacin products on its cholesterol agents Zetia and Vytorin, which the firm markets through a joint venture with Merck
Abbott Expands Pharmaceutical Pipeline With $3.7 Bil Kos Acquisition
Abbott's proposed $3.7 bil. acquisition of Kos Pharmaceuticals will help diversify Abbott's existing cardiovascular franchise, and could also expand its pipeline into respiratory diseases